



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 20/03/2018

Start	Finish		Start	Finish
SUNDAY 25 MARCH 2018				
11:00	18:30	Registration Opens	11:00	18:30
Plaza P9 & P10				
13:00	13:15	Welcome and Conference Opening Ross Dickins & Matt McCormack (Conference Co-Chairs)	13:00	13:15
Plaza P9 & P10				
Session 1 - Epigenetics Sponsored by Celgene Chairpersons: David Curtis & Richard D'Andrea				
13:15	14:00	Margaret (Peggy) Goodell - Baylor College of Medicine, Houston, USA DNA Methyltransferase 3A in Normal and Malignant Hematopoiesis	13:15	14:00
14:00	14:30	Mark Dawson - Peter MacCallum Cancer Centre, AUS Molecular mechanisms governing sensitivity and resistance to epigenetic therapies	14:00	14:30
14:30	14:45	Madison Kelly - Peter MacCallum Cancer Centre, AUS BCOR regulates myeloid differentiation and leukaemogenesis by altering the epigenome	14:30	14:45
14:45	15:00	Charles Bell - Peter MacCallum Cancer Centre, AUS Enhancer remodeling overcomes therapeutic resistance driven by non-genomic evolution in cancer	14:45	15:00
15:00	15:15	Luisa Cimmino - NYU School of Medicine, New York, USA Restoration of TET function as a therapeutic strategy in leukemia	15:00	15:15
15:15	16:00	Afternoon Tea	15:15	16:00
Plaza P9 & P10				
Session 2 - Lymphoid Malignancies: ALL & CLL Sponsored by abbvie Chairpersons: Richard Lock & Kathryn Roberts				
16:00	16:45	Iannis Aifantis - NYU School of Medicine, New York, USA lncRNAs in acute leukemia: Computational and CRISPR tools to study their functions	16:00	16:45
16:45	17:15	Mary Anne Anderson - Walter and Eliza Hall Institute, AUS Unanswered Questions in BCL2 inhibition for B Cell Malignancies	16:45	17:15
17:15	17:30	Charles de Bock - VIB/KU Leuven, Belgium Activated JAK-STAT Signaling Cooperates with HOXA9 And Drives Leukemia Development	17:15	17:30
17:30	17:45	Sebastien Malinge - Telethon Kids Insitute, AUS A murine knock-In model for the JAK3A572V activating mutation provides insights into pathobiology and therapy of T cell hematopoietic disorders	17:30	17:45
17:45	18:15	John Seymour - Peter MacCallum Cancer Centre, Melbourne, AUS Clinical Spotlight on Chronic Lymphocytic Leukemia	17:45	18:15
18:30	20:30	Welcome Reception	18:30	20:30



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 20/03/2018

Start	Finish	MONDAY 26 MARCH 2018	Start	Finish
7:00	19:00	Registration Opens	7:00	19:00
Plaza P7 & P8				
Chairpersons: Catherine Carmichael & Jess Salmon				
7:15	8:15	New Investigator "Meet the Expert" Breakfast Session	7:15	8:15
Plaza P9 & P10				
Session 3 - Stem Cells				
Chairpersons: Louise Purton & Jean-Pierre Levesque				
8:30	9:15	Dominique Bonnet - Francis Crick Institute, London, UK Leukemic stem cell interactions with the microenvironment: friend or foe?	8:30	9:15
9:15	10:00	Atsushi Iwama - Chiba University, JPN Deregulated polycomb function in the pathogenesis of myelodysplasia	9:15	10:00
10:00	10:15	Tina Schnoeder - University Hospital Jena, Germany Myeloid Leukemia Stem Cells Depend on Phospholipase C Gamma 1 (Plcg1) Signaling	10:00	10:15
10:15	10:30	Matthew McCormack - Australian Centre for Blood Diseases Lmo2 is dispensable for established Lmo2-induced T-cell acute lymphoblastic leukaemia (T-ALL) in mice	10:15	10:30
10:30	11:00	Morning Tea & Trade Display	10:30	11:00
Plaza P9 & P10				
Session 4 - Myelodysplastic Syndrome & Acute Myeloid Leukaemia				
Sponsored by Celgene				
Chairpersons: Gabriela Brumatti & Claudia Bruedigam				
11:00	11:45	Kimberly Stegmaier - Dana-Farber Cancer Institute, Boston USA Clinical Translation of AML Genomics Leveraging Functional Genomics to Identify New Targets in AML	11:00	11:45
11:45	12:15	Paula Marlton - Princess Alexandra Hospital, AUS Clinical Spotlight on Acute Myeloid Leukemia	11:45	12:15
12:15	12:45	Nikki Verrills - University of Newcastle, AUS Proteogenomic profiling reveals targetable pathways in AML	12:15	12:45
12:45	13:00	Lev Kats - Peter MacCallum Cancer Centre, AUS PRC2 and H3K27Me3-dependent regulation of gene expression by mutant IDH2 in AML	12:45	13:00
13:00	13:15	Ashwin Unnikrishnan - University of New South Wales AZA-MS: a novel multiparameter method uncovers the intracellular dynamics of Azacitidine therapy in vivo	13:00	13:15
13:15	13:45	Lunch & Trade Display	13:15	13:45
Plaza P9 & P10				
Sponsored by Leukaemia Foundation Australia				
Chairpersons: Catherine Carmichael & Jess Salmon				
13:45	14:45	New Investigator Forum – Career Development	13:45	14:45
14:45	15:15	Afternoon Tea & Trade Display	14:45	15:15
Plaza P9 & P10				
Session 5 - Donald Metcalf Oration				
Sponsored by Amgen				
Chairperson: Andrew Roberts				
15:15	16:15	John Rasko - Royal Prince Alfred Hospital, AUS Donning the cap of molecular biology while craving the gene therapy crown? From gene expression controls to clinical trials in gene therapy	15:15	16:15
16:15	16:45	Poster Preview Session	16:15	16:45
16:45	18:45	Poster Session & Trade Display	16:45	18:45



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 20/03/2018

Start	Finish	TUESDAY 27 MARCH 2018	Start	Finish
8:00	18:00	Registration Opens	8:00	18:00
Plaza P9 & P10				
Session 6 - Cell Therapy & Immunotherapy Sponsored by Novartis Chairperson: John Rasko				
8:30	9:15	Stephen Ansell - Mayo Clinic, Minnesota, USA Modulating the Immune System in Non-Hodgkin Lymphoma	8:30	9:15
9:15	10:00	Bruce Levine - Perelman School of Medicine, University of Pennsylvania, USA Chimeric Antigen Receptor T Cells: Clinical Development, FDA Approval, and What's Coming Next	9:15	10:00
10:00	10:30	Marie Bleakley - Fred Hutchinson Cancer Research Center, Seattle, USA New directions in T cell immunotherapy for leukemia	10:00	10:30
10:30	10:45	Rebecca Austin - QIMR Berghofer Medical Research Institute, AUS Immune responses to acute myeloid leukaemia	10:30	10:45
10:45	11:15	Morning Tea & Trade Display	10:45	11:15
Plaza P9 & P10				
Session 7 - Myeloproliferative Neoplasms including CML Sponsored by Bristol-Myers Squibb Chairperson: Deborah White				
11:15	11:45	Timothy Hughes - South Australian Health and Medical Research Institute, AUS Treatment Free Remission for Chronic Myeloid Leukemia in 2018	11:15	11:45
11:45	12:15	Carl Walkley - St Vincent's Institute, AUS Understanding how RNA splicing mutations contribute to myelodysplastic syndrome	11:45	12:15
12:15	12:30	Stefan Eugen Sonderegger - Australian Centre for Blood Diseases, AUS Inhibition of PRMT5 affects malignant erythroid differentiation and survival of Jak2V617F mutant precursors in myeloproliferative neoplasms.	12:15	12:30
12:30	12:45	Sebastien Jacquelin - QIMR Berghofer Medical Research Institute, AUS In vivo CRISPR editing of Dnmt3a in Jak2V617F Hematopoietic Stem Cells Induces Myelofibrosis through epigenetic reprogramming	12:30	12:45
12:45	13:00	NDLR 2018 Group Photo	12:45	13:00
13:00	14:00	Lunch & Trade Display	13:00	14:00
Plaza P9 & P10				
Session 8 - Lymphoma Chairperson: Jake Shortt				
14:00	14:30	Chan Cheah - Sir Charles Gairdner Hospital, AUS Clinical Spotlight on Lymphoma	14:00	14:30
14:30	15:00	Gemma Kelly - Walter and Eliza Hall Institute, AUS Investigating the potential of MCL-1 targeting for cancer therapy	14:30	15:00
15:00	15:15	Maher Gandhi - Princess Alexandra Hospital, AUS The Tumor Microenvironment is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma	15:00	15:15
15:15	15:30	Suzanne Cory - Walter and Eliza Hall Institute, AUS MYC-driven cells need MNT	15:15	15:30
15:30	16:00	Afternoon Tea & Trade Display	15:15	15:45
Plaza P9 & P10				
Session 9 - Myeloma Chairperson: Florian Heidel				
16:00	16:30	Andrew Spencer - Monash University, AUS Clinical Spotlight on Multiple Myeloma - A Disease in Evolution	16:00	16:30
16:30	17:00	Kyohei Nakamura - QIMR Berghofer Medical Research Institute, AUS IL-18 critically drives immunosuppression in the multiple myeloma microenvironment	16:30	16:45
Plaza P9 & P10				
Chairpersons: Gemma Kelly & Ingrid Winkler				
17:00	18:00	Equity in Science Forum	17:00	18:00
18:15	19:00	Pre-dinner Drinks	18:15	19:00
19:00	23:00	Conference Dinner	19:00	23:00



New Directions in Leukaemia Research 2018 Meeting
25 - 28 March 2018
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Program updated 20/03/2018

Start	Finish	WEDNESDAY 28 MARCH 2018	Start	Finish
8:00	13:00	Registration Opens	8:00	13:00
Plaza P9 & P10				
Session 10 - Genomics Chairperson: Andrew Perkins				
8:30	9:15	Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA New mechanisms of treatment failure in acute lymphoblastic leukemia	8:30	9:15
9:15	9:45	Anna Brown - SA Pathology, Adelaide, AUS Predisposition to Leukaemia – defining clonal evolution that harms or helps	9:15	9:45
9:45	10:00	Susan Heatley - SAHMRI, AUS Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing.	9:45	10:00
10:00	10:15	Edward Chew - Walter and Eliza Hall Institute, AUS Loss of MBD4 predisposes to familial AML with a unique mutational signature.	10:00	10:15
10:15	10:30	Pieter Van Vlierberghe - Ghent University, Belgium Oncogenic activation and therapeutic targeting of PIM1 in T-ALL and T-LBL	10:15	10:30
10:30	11:00	Morning Tea & Trade Display	10:30	11:00
Plaza P9 & P10				
Session 11 - New Therapeutic Approaches Sponsored by Leukaemia Foundation Chairpersons: Steven Lane & Luisa Cimmino				
11:00	11:30	Scott Lowe - Memorial Sloan Kettering Cancer Center, New York, USA p53 action and the consequences of p53 mutation in acute myeloid leukemia	11:00	11:30
11:30	12:00	Ingrid Winkler - Mater Institute, AUS Endothelial niche adhesive regulation of normal and malignant haematopoietic stem cells	11:30	12:00
12:00	12:30	Michelle Henderson - Children's Cancer Institute, AUS Developing new targeted agents for high-risk paediatric leukaemia	12:00	12:30
12:30	12:45	Fiona Brown - Monash University, AUS MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia	12:30	12:45
12:45	13:00	Gretchen Poortinga - Peter MacCallum Cancer Centre, AUS BET protein inhibition sensitises ribosomal DNA to localised damage and provides a robust synergistic therapeutic strategy for treating AML	12:45	13:00
13:00	13:30	Conference Close & Prize Presentations Ross Dickins & Matt McCormack (Conference Co-Chairs)	13:00	13:30
13:30	14:00	Lunch	13:30	14:00